Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 182 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14663
Sealed predictions
- FAM13A in dopamine neurons, braak-0.17 (p 0.665) → +0.23 (p 0.555)receipt 14670
Swarm cases
receipt 14670: FAM13A in dopamine neurons, braak
- power
- full sample +0.10 (p 0.690, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.328, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.319, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.23, sign flips 3; without severely affected donors +0.10 (p 0.690, n 18). fragile.
- cell type
- strongest in OPCs: +0.63 (p 0.0055, n 18) vs +0.10 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FAM13A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FAM13A · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.70 p 0.013 (needs p < 1.6e-4)
Receipts
loading the receipts